Cargando…
CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects
Post-mortem studies consistently show evidence of reduced synaptic protein levels in patients with schizophrenia. Clinically high-risk subjects show a steeper decrease in grey matter thickness and in vitro modeling using patient-derived cells implicate excessive synaptic pruning during neurodevelopm...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262376/ https://www.ncbi.nlm.nih.gov/pubmed/32490278 http://dx.doi.org/10.1016/j.ibror.2020.04.001 |
_version_ | 1783540615910260736 |
---|---|
author | Xu, Chengai Sellgren, Carl M. Fatouros-Bergman, Helena Piehl, Fredrik Blennow, Kaj Zetterberg, Henrik Brinkmalm, Ann Santillo, Alexander Frizell Lundgren, Sofia Cervenka, Simon Engberg, Göran Erhardt, Sophie |
author_facet | Xu, Chengai Sellgren, Carl M. Fatouros-Bergman, Helena Piehl, Fredrik Blennow, Kaj Zetterberg, Henrik Brinkmalm, Ann Santillo, Alexander Frizell Lundgren, Sofia Cervenka, Simon Engberg, Göran Erhardt, Sophie |
author_sort | Xu, Chengai |
collection | PubMed |
description | Post-mortem studies consistently show evidence of reduced synaptic protein levels in patients with schizophrenia. Clinically high-risk subjects show a steeper decrease in grey matter thickness and in vitro modeling using patient-derived cells implicate excessive synaptic pruning during neurodevelopment as a part of the schizophrenia pathophysiology. However, it is unclear to what extent synapse elimination is present during various stages of the disease, which is of clinical importance as in a real-world setting most subjects received their first-episode psychosis (FEP) diagnosis not until their mid-twenties. In the present study, we measured cerebrospinal fluid (CSF) concentrations of the two pre-synaptic proteins synaptosomal-associated protein 25 (SNAP-25) and synaptotagmin-1 (SYT-1), both of which are increased in conditions of ongoing synaptic degeneration, in 44 FEP subjects (mean age 29.9 years) and 21 healthy controls (25.9 years) using immunoprecipitation mass spectrometry. Neither protein was found to differ between healthy controls and patients, and they showed no correlation with symptom ratings, cognitive performance or antipsychotic medication. Additional studies in high-risk subjects in the early prodromal phase will be needed to address if excessive synapse destruction occurs before the development of overt psychotic symptoms. |
format | Online Article Text |
id | pubmed-7262376 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-72623762020-06-01 CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects Xu, Chengai Sellgren, Carl M. Fatouros-Bergman, Helena Piehl, Fredrik Blennow, Kaj Zetterberg, Henrik Brinkmalm, Ann Santillo, Alexander Frizell Lundgren, Sofia Cervenka, Simon Engberg, Göran Erhardt, Sophie IBRO Rep Article Post-mortem studies consistently show evidence of reduced synaptic protein levels in patients with schizophrenia. Clinically high-risk subjects show a steeper decrease in grey matter thickness and in vitro modeling using patient-derived cells implicate excessive synaptic pruning during neurodevelopment as a part of the schizophrenia pathophysiology. However, it is unclear to what extent synapse elimination is present during various stages of the disease, which is of clinical importance as in a real-world setting most subjects received their first-episode psychosis (FEP) diagnosis not until their mid-twenties. In the present study, we measured cerebrospinal fluid (CSF) concentrations of the two pre-synaptic proteins synaptosomal-associated protein 25 (SNAP-25) and synaptotagmin-1 (SYT-1), both of which are increased in conditions of ongoing synaptic degeneration, in 44 FEP subjects (mean age 29.9 years) and 21 healthy controls (25.9 years) using immunoprecipitation mass spectrometry. Neither protein was found to differ between healthy controls and patients, and they showed no correlation with symptom ratings, cognitive performance or antipsychotic medication. Additional studies in high-risk subjects in the early prodromal phase will be needed to address if excessive synapse destruction occurs before the development of overt psychotic symptoms. Elsevier 2020-04-13 /pmc/articles/PMC7262376/ /pubmed/32490278 http://dx.doi.org/10.1016/j.ibror.2020.04.001 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Xu, Chengai Sellgren, Carl M. Fatouros-Bergman, Helena Piehl, Fredrik Blennow, Kaj Zetterberg, Henrik Brinkmalm, Ann Santillo, Alexander Frizell Lundgren, Sofia Cervenka, Simon Engberg, Göran Erhardt, Sophie CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects |
title | CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects |
title_full | CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects |
title_fullStr | CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects |
title_full_unstemmed | CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects |
title_short | CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects |
title_sort | csf levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262376/ https://www.ncbi.nlm.nih.gov/pubmed/32490278 http://dx.doi.org/10.1016/j.ibror.2020.04.001 |
work_keys_str_mv | AT xuchengai csflevelsofsynaptosomalassociatedprotein25andsynaptotagmin1infirstepisodepsychosissubjects AT sellgrencarlm csflevelsofsynaptosomalassociatedprotein25andsynaptotagmin1infirstepisodepsychosissubjects AT fatourosbergmanhelena csflevelsofsynaptosomalassociatedprotein25andsynaptotagmin1infirstepisodepsychosissubjects AT piehlfredrik csflevelsofsynaptosomalassociatedprotein25andsynaptotagmin1infirstepisodepsychosissubjects AT blennowkaj csflevelsofsynaptosomalassociatedprotein25andsynaptotagmin1infirstepisodepsychosissubjects AT zetterberghenrik csflevelsofsynaptosomalassociatedprotein25andsynaptotagmin1infirstepisodepsychosissubjects AT brinkmalmann csflevelsofsynaptosomalassociatedprotein25andsynaptotagmin1infirstepisodepsychosissubjects AT santilloalexanderfrizell csflevelsofsynaptosomalassociatedprotein25andsynaptotagmin1infirstepisodepsychosissubjects AT lundgrensofia csflevelsofsynaptosomalassociatedprotein25andsynaptotagmin1infirstepisodepsychosissubjects AT cervenkasimon csflevelsofsynaptosomalassociatedprotein25andsynaptotagmin1infirstepisodepsychosissubjects AT engberggoran csflevelsofsynaptosomalassociatedprotein25andsynaptotagmin1infirstepisodepsychosissubjects AT erhardtsophie csflevelsofsynaptosomalassociatedprotein25andsynaptotagmin1infirstepisodepsychosissubjects AT csflevelsofsynaptosomalassociatedprotein25andsynaptotagmin1infirstepisodepsychosissubjects |